Cellares, an Integrated Development and Manufacturing Organization (IDMO), has expanded its partnership with the University of Wisconsin (UW) School of Medicine and Public Health to support the clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy.
VivaMed BioPharma has entered into a collaboration with Syngene International, a contract research development and manufacturing organization (CRDMO), to strengthen its AI-powered drug discovery and validation infrastructure. The partnership is designed to integrate VivaMed’s AI-derived therapeutic hypotheses with Syngene’s preclinical
Cross-border licensing deals between Greater China-based biopharmaceutical companies and global drugmakers reached an unprecedented $137.7 billion in 2025, a nearly tenfold increase from 2021’s $13.9 billion, according to China-based data provider PharmCube. Industry analysts now predict 2026 will surpass that
MGS, a contract development and manufacturing organization (CDMO), has introduced a new manufacturing facility in Richfield, Wisconsin. The 300,000-square-foot site was developed to support a global pharmaceutical partner’s expanding drug delivery platform and to meet increasing demand for high-volume manufacturing
In an industry where the wrong manufacturing partnership can derail a drug program, and the right one can accelerate it, biotech leaders face mounting pressure to make smarter, faster decisions about their CDMOs. But are they asking the right questions?
Lonza has strengthened its Advanced Synthesis offering to provide phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates. The move integrates the company’s ADC technology platform into its Advanced Synthesis portfolio, expanding its contract development
Johnson & Johnson has announced a more than $1 billion investment to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site will expand the company’s U.S. manufacturing capacity as it advances its portfolio and pipeline of
Rezon Bio has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar at its Warsaw-Duchnice facility. The approval enables commercial supply to the United States and follows earlier European Medicines Agency (EMA)
Catalent has announced a strategic partnership with S.Biomedics to support the development and manufacturing of TED-A9, an allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy for the treatment of Parkinson’s disease. The collaboration is designed to establish a scalable,
ValGenesis, Inc. has announced that a leading fill-finish contract development and manufacturing organization (CDMO) specializing in sterile filling has adopted its electronic logbook application to modernize logbook management across its manufacturing facilities. The implementation replaces hundreds of paper logbooks that
